Intended for healthcare professionals

Rapid response to:

Research Methods & Reporting

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2089 (Published 30 June 2016) Cite this as: BMJ 2016;353:i2089

Rapid Response:

Re: GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

Thank you Professor Treweek for responding to my comment. Perhaps, what you are saying is that our best estimate is that compared with warfarin, dabigatran will “probably” result in 8 fewer deaths per 1000 patients; however, our findings are compatible with the possibility that that there might be no (additional) risk reduction. Would this be a fair statement to make?

Competing interests: No competing interests

19 August 2016
Mohammed T. Ansari
Adjunct Professor
University of Ottawa
206-2470 Southvale Crescent, Ottawa, ON, CANADA